healthandpharma12h
New Oral SERD Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
emjreviews.com16h
Next-Gen SERD Improves Outcomes in Resistant Breast Cancer: SABCS 2024
Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
Lilly’s Phase III SERD breast cancer study has success in certain patients
The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and ...
The Pharma Letter20h
Lilly’s imlunestrant takes aim at oral SERD market
Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...